

## A Message From Our CEO

Building Upon Our Strong Foundation to Advance Access for Patients



In 2025, Viatriis marked its five-year anniversary, an important milestone to reflect on how far we've come and, more importantly, where we're headed.

In a short time, we have built upon our strong foundation, strengthened our capabilities and positioned Viatriis for a more impactful future built on execution, integrity, collaboration and a shared mission. At the center of our work is a clear purpose: to provide high-quality medicines to patients around the world. In 2025, we reached approximately 1 billion patients and played a relevant role in supporting healthcare systems and societies across the globe.

Looking ahead, we will continue to focus on operating responsibly and working to further advance sustainable practices across our business. This includes remaining committed to the UN Global Compact principles on human rights, labor, the environment and anti-corruption.

We continue to make meaningful progress in three key areas: expanding access to medicines, supporting our people and reducing our environmental impact.

Delivering on our mission to empower people worldwide to live healthier at every stage of life means we are continually working to address unmet medical needs. In 2025, we demonstrated the strength of our scientific and regulatory capabilities. We advanced our pipeline with five positive Phase 3 data readouts across several therapeutic areas including pain, ophthalmology, women's health and mental health. We also expanded our innovative cardiovascular portfolio with the approval of Inpefa® (sotagliflozin) in the United Arab Emirates, and we added to our robust complex injectables portfolio with the first FDA approval of a generic iron sucrose.

Our progress is driven by the ingenuity of our colleagues. In 2025, Viatriis was certified as a Great Place to Work in more than 50 countries and recognized among Fortune's World's Best Workplaces, as well as Forbes' annual list of the World's Best Employers for the fifth year in a row. These recognitions reflect our commitment to a culture where people can do meaningful work and perform at their best.

We also honored our commitment to reducing our environmental impact while working to uphold a reliable supply of medicine. We made significant progress on our water and waste goals and our work to reduce GHG emissions in our supply chain, and were named to Time Magazine's World's Most Sustainable Companies 2025 for the second consecutive year.

Importantly, we also completed our enterprise-wide strategic review in 2025, positioning us to become a more focused, efficient and future-ready organization. By sharpening our priorities and aligning resources accordingly, we are driving our base business, fueling our innovative portfolio and modernizing for sustainable growth.

I want to thank our colleagues around the world for their commitment and tireless efforts to make a positive impact for patients. Because of their work, Viatriis is entering its next chapter stronger, more focused and better positioned to deliver on our mission and continue improving access to medicines.

**Scott A. Smith**  
Chief Executive Officer, Viatriis

## A Message From Our Chair of the Board



Viatriis continues to work closely with partners around the world to leverage our collective capabilities and help address the complex challenges facing healthcare systems today.

Through these collaborations, we are making meaningful contributions to improving access to medicines and supporting better health outcomes for patients globally.

In many ways, 2025 was a pivotal year for Viatriis. It marked our five-year anniversary and the completion of our enterprise-wide strategic review that will help guide the company's next phase of growth. We also saw important progress in our pipeline, further strengthening our ability to address unmet medical needs.

As Chair of the Board, I am proud of Viatriis' strong foundation and clear sense of purpose. The Board remains focused on management's execution of the company's strategy and the continued advancement of responsible and sustainable business practices.

On behalf of the Board, I want to thank all of Viatriis' colleagues for their dedication. Their efforts are essential to delivering on our mission, improving access to medicines for patients and positioning Viatriis for continued impact in the years ahead.

**Melina Higgins**  
Chair of the Board of Directors, Viatriis

### Stay Connected

Media Relations  
+1.724.514.1968  
Communications@viatriis.com

Investor Relations  
+1.724.514.1813  
InvestorRelations@viatriis.com



Viatriis.com



LinkedIn



@ViatriisInc



@ViatriisInc



YouTube

*Stay Connected*

**Media Relations**  
+1.724.514.1968  
Communications@viatris.com

**Investor Relations**  
+1.724.514.1813  
InvestorRelations@viatris.com



[Viatriis.com](https://www.viatris.com)



[LinkedIn](https://www.linkedin.com/company/viatris)



[@ViatriisInc](https://twitter.com/ViatriisInc)



[@ViatriisInc](https://www.instagram.com/ViatriisInc)



[YouTube](https://www.youtube.com/ViatriisInc)